Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC-5404-FU in Advanced Solid Tumors
NCT04834778Phase 1Completed
- Sponsor
- HiberCell
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HC-5404 in renal cell carcinoma (RCC), gastric cancer (GC), breast cancer and 2 more (8 cohorts), sponsored by HiberCell. Primary endpoints: Maximum Tolerated Dose, Dose-Limiting Toxicities and 4 more. Started Jun 2021; status: completed.
02
Drugs
HC-5404
03
Conditions
renal cell carcinoma (RCC)gastric cancer (GC)breast cancersmall cell lung cancer (SCLC)solid tumor
Beyond the preview
Go deeper on NCT04834778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04834778.